FGFR2 Y375C

CI-VAR-00004806Explore in graph →CIViC 3356

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm of Unknown Primary1
FGFR2 Y375C	Futibatinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID11640 In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC) PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC	civic
Unmapped disease1unmapped disease
FGFR2 Y375C	(functional)	Functional	D	Supports Gain Of Function	3	submitted	EID9355 FGFR2 Y375C was expressed in rat chondrosarcoma chondrocytes and was shown to increase activation of ERK and LRP6 relative to wild-type, as measured by western blot. FGFR2 Y375C also caused increased … (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.